Sirpiglenastat

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Sirpiglenastat (DRP-104) 是一种广泛作用的谷氨酰胺 (glutamine) 拮抗剂。Sirpiglenastat通过直接靶向肿瘤代谢并同时诱导有效的抗肿瘤免疫反应而具有抗癌作用。

Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.

Sirpiglenastat (DRP-104) treatment shows broad immune cell modulation effects including increased T, NK, and macrophages. Sirpiglenastat decreases pro-tumorigenic cytokines such as VEGF and KC (IL-8).

CT26 bearing mice treated with Sirpiglenastat (DRP-104) (0.5 mg/kg; s.c.; once a day; for 5 days) shows tumor growth inhibition at day 12 of 90%. Median survival days are 36 days. Sirpiglenastat (0.5 mg/kg; s.c) treatment significantly inhibits tumor growth in the H22 model.Animal Model:CT26 bearing mice Dosage:0.5 mg/kg Administration:s.c.; once a day; for 5 days Result:Showed tumor growth inhibition in mice.

——

Others

Other Targets

Glutaminase

——

——

2079939-05-0

441.48

C22H27N5O5

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 100 mg/mL (226.51 mM; 超声助溶 )

C([C@@H](C(N[C@H](C(OC(C)C)=O)CCC(C=[N+]=[N-])=O)=O)NC(C)=O)C=1C=2C(NC1)=CC=CC2

——

(-20℃)

With Ice Pack

≥ 2 years